| Primary Identifier | MGI:2447530 | Allele Type | Transgenic |
| Attribute String | Inserted expressed sequence | Gene | Tg(MMTV-vHaras)SH1Led |
| Strain of Origin | (CD-1 x C57BL/6J)F1 | Is Recombinase | false |
| Is Wild Type | false |
| description | Multiple transgenic lines were produced. Both male and female transgenic mice develop malignant lymphoid tissue and mammary and salivary gland tumors as early as 5 weeks of age. Half of the female transgenic animals develop tumors by 6 months of age. Histological analysis of mammary tumors revealed most of the tumors were adenocarcinomas and were locally invasive with some cases of metastasis to liver and/or lung. The tumors were found to express the transgene transcript. Protein-tyrosine phosphatase epsilon mRNA and protein was found to be highly expressed only in mammary tumors. In 20% of the transgenic mice diffuse benign hyperplasia develops in the Harderian lacrimal gland causing bilateral exophthalmia. Hemizygous transgenic female mice develop tumors by delivery time of first litter with tumorigenesis accelerated by pregnancy. Hemizygous transgenic male mice develop large salivary gland tumors in the neck and eye opacity by 5 to 6 months of age. Hemizygous males have low sperm counts and high incidence of sperm abnormalities resulting in low fertility. |
| molecularNote | This transgene contains the MMTV (mouse mammary tumor virus) promoter and an allele of the Harvey rat sarcoma viral oncogene (viral) carrying two activating point mutations: one in codon 12, Gly12Arg, and one in codon 59, Ala59Thr. The transgenic construct was reported to be highly expressed in the mammary glands and salivary glands, expressed in the Harderian glands, thymus and spleen, slightly expressed in the lungs, ovaries and kidneys, and little or no expression was reported to have been observed in the liver and skeletal muscle of these mice. |
